Frontiers in psychiatry

Real-world results of nasal esketamine and intravenous ketamine treatments for hard-to-treat depression in a community clinic

Psychedelic Science Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

Intravenous ketamine and intranasal esketamine are NMDA receptor antagonists used for treatment-resistant depression.

  • Both ketamine and esketamine have shown effectiveness in controlled trials for treatment-resistant depression.
  • Observational evidence regarding their use in real-world community settings remains limited.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

The authors are employed at Ketamine Health and Wellness Clinics of Ohio, a community psychiatric clinic that offers both intranasal esketamine and intravenous ketamine as clinical services. This affiliation is disclosed in the interest of transparency.
PubMed

Related papers

Nov '22
Folic acid supplements and malaria risk and severity in people using antifolate malaria drugs in affected areas
cited by 30 papers
systematic review
Nov '25
Comparing intravenous ketamine and esketamine for depression: a review and combined analysis
top 20% journal
journal article
Nov '25
Factors that predict how people with hard-to-treat depression respond to IV ketamine and nasal esketamine treatments
top 10% journal
cited by 3 papers
journal article
Sep '21
Ketamine and similar brain chemicals for treating depression in adults with major unipolar depression
cited by 37 papers
systematic review
May '18
Psychological treatments for adults with depression that doesn't respond to usual care
cited by 53 papers
systematic review
Jun '26
Oral Slow-Release Ketamine for Hard-to-Treat Depression: Two Clinical Trials
top 2% journal
cited by 1 paper
Jan '26
Comparing nasal racemic ketamine and esketamine for hard-to-treat depression in real-world patients
top 5% journal
journal article
Sep '25
Comparing repeated ketamine infusions and nasal esketamine in hard-to-treat depression
top 10% journal
cited by 4 papers
comparative study

Featured in

Psychedelic SciencePsychedelic ScienceIssue #48
Psychedelics during adolescence reshaped adult social behavior in rats — here's the circuit
↗

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the psychedelic science brief

issue #48
Psychedelics during adolescence reshaped adult social behavior in rats — here's the circuit
-2 days ago7 studies
issue #47
Psilocybin rewired prefrontal circuits in mice — but only for one specific type of cognitive failure
5 days ago7 studies
issue #46
Psilocybin cut two specific brain chemicals in depressed patients — here's what that means
1 week ago7 studies
issue #44
Psilocybin rewires brain feedback circuits for weeks after a single dose, new evidence shows
2 weeks ago7 studies
issue #43
A pill form of ketamine cut dissociation to near-zero vs. nasal spray's 29.6-point spike — but missed its main antidepressant target
3 weeks ago7 studies
issue #42
At-home ketamine injections cut depression scores by more than half in 3,870 patients
4 weeks ago8 studies
issue #41
Psychedelics disrupt brain signal flow in both humans and mice across LSD, psilocybin, and MDMA
5 weeks ago7 studies
issue #40
Inhaled 5-MeO-DMT cut postpartum depression scores by 35 points
6 weeks ago7 studies
issue #39
Psilocybin's antidepressant effects lasted 12 months in 126 treatment-resistant patients
7 weeks ago7 studies
issue #38
Buprenorphine extends ketamine's anti-suicide effects for 4 weeks in depression trial
8 weeks ago7 studies
explore the archive
See more issues from the psychedelic science brief